Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713437 · ClinicalTrials.gov registry record
Measurement of Beta Cell Death in Individuals With Cystic Fibrosis
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 40
- Enrollment target
NCT03713437 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 40 participants.
The verdict
NCT03713437 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants will have a blood sample drawn in order to measure the levels of differentially methylated insulin DNA.
Interventions
- DIAGNOSTIC_TEST Measurement of differentially methylated insulin DNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2021-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03713437
The ClinicalTrials.gov registry entry for NCT03713437 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Measurement of differentially methylated insulin DNA is the first listed.
NCT03713437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03713437 about?
NCT03713437 is a clinical study titled "Measurement of Beta Cell Death in Individuals With Cystic Fibrosis". This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants ...
What is the current status of trial NCT03713437?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2019-04-04. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03713437?
The interventions under investigation include: Measurement of differentially methylated insulin DNA (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03713437?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.